Morgan Stanley Royalty Pharma PLC Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Royalty Pharma PLC stock. As of the latest transaction made, Morgan Stanley holds 41,029,832 shares of RPRX stock, worth $1.38 Billion. This represents 0.09% of its overall portfolio holdings.

Number of Shares

41,029,832

Previous 39,532,770 3.79%

Holding current value

$1.38 Billion

Previous $1.01 Billion 26.65%

% of portfolio

0.09%

Previous 0.07%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$25.75 - $33.86 $38.5 Million - $50.7 Million	1,497,062 Added 3.79%	41,029,832 $1.28 Billion
Q4 2024 Feb 14, 2025	SELL	$24.28 - $28.39 $37.5 Million - $43.9 Million	-1,545,393 Reduced 3.76%	39,532,770 $1.01 Billion
Q3 2024 May 14, 2025	SELL	$25.63 - $29.27 $78.3 Million - $89.4 Million	-3,055,283 Reduced 6.92%	41,078,163 $1.16 Billion
Q3 2024 Nov 14, 2024	SELL	$25.63 - $29.27 $78.3 Million - $89.4 Million	-3,055,283 Reduced 6.92%	41,078,163 $1.16 Billion
Q2 2024 May 14, 2025	BUY	$26.26 - $29.9 $121 Million - $138 Million	4,600,676 Added 11.64%	44,133,446 $1.16 Billion
Q2 2024 Oct 17, 2024	SELL	$26.26 - $29.9 $2.22 Million - $2.52 Million	-84,439 Reduced 0.19%	44,133,446 $1.16 Billion
Q2 2024 Aug 14, 2024	SELL	$26.26 - $29.9 $2.22 Million - $2.52 Million	-84,439 Reduced 0.19%	44,133,446 $1.16 Billion
Q1 2024 Oct 17, 2024	BUY	$27.46 - $31.33 $2.32 Million - $2.65 Million	84,439 Added 0.19%	44,217,885 $1.34 Billion
Q1 2024 Aug 16, 2024	SELL	$27.46 - $31.33 $58.7 Million - $66.9 Million	-2,136,381 Reduced 4.61%	44,217,885 $1.34 Billion
Q1 2024 May 15, 2024	SELL	$27.46 - $31.33 $58.7 Million - $66.9 Million	-2,136,381 Reduced 4.61%	44,217,885 $1.34 Billion
Q4 2023 Aug 16, 2024	BUY	$26.21 - $29.22 $58.2 Million - $64.9 Million	2,220,820 Added 5.03%	46,354,266 $1.3 Billion
Q4 2023 Feb 13, 2024	SELL	$26.21 - $29.22 $46.6 Million - $52 Million	-1,778,349 Reduced 3.69%	46,354,266 $1.3 Billion
Q3 2023 Nov 15, 2023	BUY	$26.26 - $31.38 $18.5 Million - $22.1 Million	702,754 Added 1.48%	48,132,615 $1.31 Billion
Q2 2023 Aug 14, 2023	BUY	$29.6 - $36.56 $2.35 Million - $2.9 Million	79,403 Added 0.17%	47,429,861 $1.46 Billion
Q1 2023 May 15, 2023	SELL	$32.77 - $39.4 $62.1 Million - $74.7 Million	-1,895,574 Reduced 3.85%	47,350,458 $1.71 Billion
Q4 2022 Feb 14, 2023	SELL	$39.17 - $44.04 $36.8 Million - $41.4 Million	-940,129 Reduced 1.87%	49,246,032 $1.95 Billion
Q3 2022 Nov 14, 2022	SELL	$39.88 - $44.65 $54.1 Million - $60.6 Million	-1,357,010 Reduced 2.63%	50,186,161 $2.02 Billion
Q2 2022 Oct 27, 2022	SELL	$37.53 - $44.22 $75 Million - $88.4 Million	-1,998,617 Reduced 3.73%	51,543,171 $2.17 Billion
Q2 2022 Aug 15, 2022	SELL	$37.53 - $44.22 $75 Million - $88.4 Million	-1,998,617 Reduced 3.73%	51,543,171 $2.17 Billion
Q1 2022 Oct 27, 2022	BUY	$37.46 - $42.44 $74.9 Million - $84.8 Million	1,998,617 Added 3.88%	53,541,788 $2.09 Billion
Q1 2022 May 13, 2022	SELL	$37.46 - $42.44 $101 Million - $114 Million	-2,688,902 Reduced 4.78%	53,541,788 $2.09 Billion
Q4 2021 Feb 14, 2022	SELL	$35.17 - $42.48 $37.8 Million - $45.6 Million	-1,074,621 Reduced 1.88%	56,230,690 $2.24 Billion
Q3 2021 Nov 15, 2021	BUY	$36.14 - $42.24 $2.07 Billion - $2.42 Billion	57,305,311 New	57,305,311 $2.07 Billion

Others Institutions Holding RPRX

# of Institutions

484

Shares Held

283M

Call Options Held

2.51M

Put Options Held

941K

View Full List

About Royalty Pharma plc

Ticker RPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 437,139,008
Market Cap $14.8B
Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...

More about RPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account